Current drug development for antidepressants and ideas addressing downstream glutamate: The ketamine example

摘要

Novel antidepressant drug development remains anelusive goal despite tests of scores of agents withmolecular mechanisms that go beyond those involvedin the action of currently marketed antidepressants.Clinical trials of agents with supposedly promising novelmechanisms for treating symptoms of depression havebeen followed by disappointing, clinically insignificantresults in Phase 2 or Phase 3. It is unclear, however, howmany of these studies provide interpretable data thatrule out a specific mechanism of antidepressant action.